Ibrutinib plus bortezomib plus R-CHOP for higher-risk DLBCL: Efficacy, feasibility and molecular predictors

被引：0
|
作者：
Denker, S. [1 ,2 ]
Bittner, A. [1 ,2 ]
Frick, M. [1 ]
Kase, J. [1 ]
Hoffmann, J. [3 ]
Trenker, C. [3 ]
Keller, U. [2 ,4 ,5 ,6 ,7 ]
Bogner, C. [8 ]
Huttmann, A. [9 ]
Duhrig, J. [9 ]
Janz, M. [4 ,7 ]
Mathas, S. [4 ,7 ]
Marks, R. [10 ,11 ]
Krohn, U. [10 ,11 ]
Bhattacharya, A. [4 ]
Na, I. -K [1 ,2 ]
Gebauer, B. [4 ]
Savic, L. J. [4 ]
Hubner, N. [7 ]
Akalin, A. [12 ]
Eils, R. [2 ]
Bullinger, L. [1 ,2 ,5 ,6 ]
Schmitt, C. A. [1 ,7 ,13 ]
机构：
[1] Charite Univ Med Berlin, Med Klin mS Hamatol Onkol & Tumorimmunol, Campus Virchow Klinikum, Berlin, Germany
[2] Berlin Inst Hlth BIH, Berlin, Germany
[3] Philipps Univ Marburg, Univ Hosp Giessen & Marburg, Dept Hematol, Oncol,Immunol, Marburg, Germany
[4] Charite Univ Med Berlin, Berlin, Germany
[5] German Canc Res Ctr, Heidelberg, Germany
[6] German Canc Consortium DKTK, Heidelberg, Germany
[7] Max Delbruck Ctr Mol Med, Berlin, Germany
[8] Tech Univ Munich, Med Clin & Policlin 2, Klinikum Rechts Isar, Munich, Germany
[9] Univ Duisburg Essen, Univ Klinikum Essen, Klin Hamatol, Essen, Germany
[10] Univ Freiburg, Dept Hematol Oncol Stem Cell Transplantat, Fac Med, Freiburg, Germany
[11] Univ Freiburg, Dept Hematol Oncol Stem Cell Transplantat, Med Ctr, Freiburg, Germany
[12] Max Delbruck Ctr Mol Med, Berlin Inst Med Syst Biol, Bioinformat & Omics Data Sci Platform, Berlin, Germany
[13] Kepler Univ Hosp, Dept Hematol & Oncol, Linz, Austria
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V104
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [21] RANDOMIZED PHASE II STUDY OF R-CHOP PLUS ENZASTAURIN VERSUS R-CHOP IN THE FIRST-LINE TREATMENT OF PATIENTS WITH INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) - PRELIMINARY ANALYSIS
    Hainsworth, J. D.
    Arrowsmith, E. R.
    Mccleod, M.
    Fayad, L. E.
    Hamid, O.
    Davis, L.
    Lin, B.
    ANNALS OF ONCOLOGY, 2011, 22 : 107 - 107
  • [22] Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601
    Till, Brian G.
    Li, Hongli
    Bernstein, Steven H.
    Fisher, Richard I.
    Burack, Richard
    Rimsza, Lisa M.
    Floyd, Justin
    DaSilva, Marco A.
    Moore, Dennis F.
    LeBlanc, Michael
    Friedberg, Jonathan W.
    BLOOD, 2014, 124 (21)
  • [23] Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
    Nowakowski, Grzegorz S.
    Willenbacher, Wolfgang
    Greil, Richard
    Larsen, Thomas S.
    Patel, Krish
    Jaeger, Ulrich
    Manges, Robert F.
    Truemper, Lorenz
    Everaus, Hele
    Kalakonda, Nagesh
    Brown, Peter
    Jorgensen, Judit Meszaros
    Cunningham, David
    Dell'Aringa, Justine
    Fox, Brian
    Rubio, Neus Domper
    Kilavuz, Nurgul
    Casadebaig, Marie-Laure
    Manzke, Oliver
    Munoz, Javier
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (02) : 222 - 232
  • [24] Phase I Trial of Carfilzomib plus R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
    Hill, Brian T.
    Dean, Robert M.
    Jagadeesh, Deepa
    Garcia, Alex V. Mejia
    Pohlman, Brad
    Winter, Allison M.
    Krauspe, Ethan
    Collier, Patrick
    D'Andrea, Christopher
    Morrison, Ashley
    Lehmann, Sarah
    Tomlinson, Benjamin K.
    Cooper, Brenda
    de Lima, Marcos
    Ondrejka, Sarah L.
    Hsi, Eric D.
    Caimi, Paolo
    BLOOD, 2018, 132
  • [25] Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
    Grzegorz S. Nowakowski
    Wolfgang Willenbacher
    Richard Greil
    Thomas S. Larsen
    Krish Patel
    Ulrich Jäger
    Robert F. Manges
    Lorenz Trümper
    Hele Everaus
    Nagesh Kalakonda
    Peter Brown
    Judit Meszaros Jørgensen
    David Cunningham
    Justine Dell’Aringa
    Brian Fox
    Neus Domper Rubio
    Nurgul Kilavuz
    Marie-Laure Casadebaig
    Oliver Manzke
    Javier Munoz
    International Journal of Hematology, 2022, 115 : 222 - 232
  • [26] Phase II study of sequential R-CHOP plus yttriurn 90 ibritumomab tiuxetan as first-line therapy for elderly patients at high risk with DLBCL
    Reddy, GK
    CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (04): : 267 - 268
  • [27] Safety Results of a Phase I Study of Zandelisib plus R-CHOP in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)
    Jagadeesh, Deepa
    Caimi, Paolo
    Winter, Allison
    Wei, Wei
    Pohlman, Brad
    D'Andrea, Christopher
    Rhoades, Emily
    Dean, Robert M.
    Hill, Brian T.
    BLOOD, 2023, 142
  • [28] POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.
    Tilly, Herve
    Flowers, Christopher
    Friedberg, Jonathan W.
    Herbaux, Charles
    Morschhauser, Franck
    Sehn, Laurie Helen
    Sharman, Jeff Porter
    Trneny, Marek
    Lee, Calvin
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
    Mounier, N
    Briere, J
    Gisselbrecht, C
    Emile, JF
    Lederlin, P
    Sebban, C
    Berger, F
    Bosly, A
    Morel, P
    Tilly, H
    Bouabdallah, R
    Reyes, F
    Gaulard, P
    Coiffier, B
    BLOOD, 2003, 101 (11) : 4279 - 4284
  • [30] A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma
    Hainsworth, John D.
    Arrowsmith, Edward R.
    McCleod, Michael
    Hsi, Eric D.
    Hamid, Oday
    Shi, Peipei
    Lin, Boris K.
    Fayad, Luis E.
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 216 - 218
12345